Filing Flows › Nuo Therapeutics (AURX) › Q4 2025
Nuo Therapeutics (AURX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 30, 2026
Nuo Therapeutics (AURX) reported revenue of $1.1M for the fourth quarter 2025 (Q4 2025), +178% from a year earlier and +6% from the quarter before. Operating margin was -52.8%, net loss $578K (52.7% of revenue).
Nuo Therapeutics, Q4 2025: revenue $1.1M (+178% year over year), operating margin -52.8%, net loss $578K, operating cash flow −$423K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | +6% | +178% |
| Operating profit | −$579K | — | — |
| Net earnings | −$578K | — | — |
| Operating cash flow | −$423K | — | — |
What changed
Revenue was $1.1M in Q4 2025, up 178% year over year and up 6% from the previous quarter. Product was the largest line at 93% of revenue.
Gross margin was 62.8%, down 15.4 points from Q4 2024. Operating costs exceeded revenue by $579K, an operating margin of -52.8%. Operating expenses grew 35% against revenue growth of 178%. The quarter ended with a net loss of $578K, wider than the previous quarter's $538K loss.
Operating cash flow was −$423K. Non-cash charges added back $24K of depreciation and $24K of share-based compensation. Working capital and other items added $108K. Capital expenditures of $43K exceeded it, leaving free cash flow of −$466K.
Questions
What was Nuo Therapeutics' revenue in the fourth quarter 2025?
Nuo Therapeutics (AURX) reported revenue of $1.1M for the fourth quarter 2025 (Q4 2025), +178% from a year earlier and +6% from the quarter before.
Was Nuo Therapeutics profitable in the fourth quarter 2025?
Operating loss was $579K (-52.8% of revenue) and net loss $578K.
Source: Nuo Therapeutics 10-K on SEC EDGAR.